PharmaForceIQ’s AI-Driven Omnichannel Platform Boosts HCP Engagement and NRx by 97%
Best-in-Class Omnichannel Healthcare Marketing Platform, PharmaForceIQ delivers a hyper-targeted omnichannel launch driving a 2X increase in HCP engagement rate over benchmarks and a 97% new prescription (NRx) coverage in a highly crowded Lung Oncology Market
HINGHAM, Mass., Feb. 21, 2023 /PRNewswire/ -- PharmaForceIQ (pharmaforceiq.com), an AI-driven omnichannel platform for hyper-targeted HCP marketing, today announced impressive results from a 24-month HCP campaign for a 2nd to market NSCLC drug in which Medscape (WebMD) was leveraged as one of the high performing channels.
PharmaForceIQ was founded to integrate & orchestrate the entire life sciences HCP marketing ecosystem. In 2020, the company initiated a project for a rare 2nd to market NSCLC targeted therapy which had limited marketing resources and a small sales team, hence was looking to optimize its HCP targeting efforts i.e., increase its HCP share of voice (SOV) when it matters most.
PharmaForceIQ partnered with Medscape and other 3rd party partners to deliver the “Right Message, at the Right Time, to the Right Physician via the Right Channel “by:
- Identifying and characterizing patients and treating HCP targets in “Real Time” via the use of real-world data (RWD) i.e., “triggers”
- Developing customized message sequences based on the different HCP archetypes and their channel preferences
- Deploying the HCP triggers in an omnichannel way based on physician affinity across sales rep CRM (Veeva), digital, peer to peer and through 3rd party endemic digital partners (including Medscape’s Next Best Engagement program)
- Integrating all of the above in a near real-time dashboard that monitored performance metrics and triggered next best actions
Among the soon to be published results, HCP engagement rates for the brand more than doubled compared to the industry standard during the first 12 months of implementation, and has remained consistent over an ongoing period of 24 months. The Medscape NBE channel was the highest performing platform across the 3rd party partners in terms of overall engagement rates, accounting for about 45% of engagements in the first 12 months. As a testament to the hyper-targeted omnichannel approach, 97% of all new patient prescriptions (NRx) in year 1 of launch were traced and attributed directly back to the triggers and engagements generated from the PharmaForceIQ platform.
“These results mean the brand was able to focus and track its physician marketing efforts to when it matters most i.e., when a physician has a potential patient, without sacrificing SOV with target HCPs and prescription opportunities,” said Stephen Onikoro, Senior Principal at PharmaForceIQ. “The power of this approach is in the ability to target each individual HCP anywhere in the ecosystem whether endemic, non-endemic, sales rep CRM or peer to peer events”
“Our partnership with PharmaForceIQ on the Next Best Action Omnichannel project provided a real-world case study of the performance of Medscape’s Next Best Engagement approach. We were thrilled to have 97% of the brand’s first year’s NRx attributed back to our combined efforts” said Young Hur, Associate Director, Commercial Clinical Strategy”
About PharmaForceIQ
PharmaForceIQ is the only omnichannel HCP marketing platform that integrates all data, field, digital and endemic channels to activate the Right HCPs, when they have an eligible patient Right Time, through the Right Channel, and with the Right Message. All powered by our proprietary HCP affinity data. Visit our website www.pharmaforceiq.com or email [email protected] to learn more.
About Medscape
Medscape is the leading online global destination for physicians and healthcare professionals worldwide, offering the latest medical news and expert perspectives; essential point-of-care drug and disease information; and relevant professional education and CME. Our mission is to improve patient care with comprehensive clinical information and resources essential to physicians and healthcare professionals.
SOURCE PharmaForceIQ LLC
Share this article